Doxorubicin hydrochloride (liposomal)

DRUG5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Sequus Pharmaceuticals

Conditions

HIV InfectionsSarcoma, Kaposi

Phase 2

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

CompletedNCT00001059

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Sarcoma, Kaposi

End: 1998-08-31Target: 120Updated: 2012-04-17

Phase 3

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

CompletedNCT00002319

Sequus PharmaceuticalsHIV Infections, Sarcoma, Kaposi

Updated: 2005-06-24

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

CompletedNCT00002105

Sequus PharmaceuticalsHIV Infections, Sarcoma, Kaposi

Target: 220Updated: 2005-06-24

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

Sequus PharmaceuticalsHIV Infections, Sarcoma, Kaposi

Target: 225Updated: 2005-06-24

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

CompletedNCT00002147

Sequus PharmaceuticalsHIV Infections, Sarcoma, Kaposi

Updated: 2005-06-24